Equity awards for CONMED (CNMD) VP Matthew Schabacker detailed in Form 4

Rhea-AI Filing Summary

Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.

CONMED Corp reported that executive Matthew Schabacker, VP GM Advanced Surgical, received equity awards consisting of 9,827 restricted stock units and options to purchase 11,646 shares of common stock. The RSUs generally vest over three years, while the stock options generally vest in equal parts over four years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schabacker Matthew

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP GM Advanced Surgical

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	03/02/2026		A		9,827		(1)	03/02/2036	Common Stock	9,827	$0	9,827	D
Options To Purchase Common Stock	$45.79	03/02/2026		A		11,646		(2)	03/02/2036	Common Stock	11,646	$0	11,646	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

2. The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

	/s/ Thomas Fistek for Matthew Schabacker by Power of Attorney	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CONMED (CNMD) report for Matthew Schabacker?

CONMED reported that executive Matthew Schabacker received 9,827 restricted stock units and options on 11,646 shares. These equity awards are part of the company’s 2025 Long-Term Incentive Plan and vest over multi-year periods tied to continued service.

How many RSUs did CONMED (CNMD) grant to Matthew Schabacker?

CONMED granted 9,827 restricted stock units to Matthew Schabacker. Each RSU represents a contingent right to receive one share of common stock, generally vesting over three years in 33%, 33%, and 34% annual installments under the 2025 Long-Term Incentive Plan.

What stock options did CONMED (CNMD) award to Matthew Schabacker?

CONMED awarded stock options to purchase 11,646 shares of common stock to Matthew Schabacker. These options were granted under the 2025 Long-Term Incentive Plan and generally vest in equal 25% installments each year over four years, starting one year after the grant date.

When do Matthew Schabacker’s CONMED (CNMD) RSUs vest?

The 9,827 RSUs granted to Matthew Schabacker generally vest over three years. About 33% vest one year after the grant date, another 33% in the second year, and the remaining 34% in the third year, subject to plan terms.

Over what period do Matthew Schabacker’s CONMED (CNMD) stock options vest?

The options to purchase 11,646 CONMED shares granted to Matthew Schabacker generally vest over four years. Vesting occurs in equal 25% portions, with the first installment one year after the grant date and additional installments in each of the following three years.

Under which plan were Matthew Schabacker’s CONMED (CNMD) equity awards granted?

Both the restricted stock units and stock options granted to Matthew Schabacker were issued under CONMED’s 2025 Long-Term Incentive Plan. This plan governs the vesting schedules and other terms and conditions of the awards for eligible executives and employees.